Wells Fargo analyst Stan Berenshteyn lowered the firm’s price target on Omnicell (OMCL) to $40 from $49 and keeps an Equal Weight rating on the shares. The firm continues to see risks to Product revenue estimates in 2025 and elevated risks from health systems’ PnL.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio